Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients

Nephron - Clinical Practice

Volumn 114, Issue 4, 2010, Pages

  Lee, Hyun Kee ^a   Kim, Yoon Ji ^a   Jeong, Jin Uk ^a   Park, Jung Sik ^a   Chi, Hyun Sook ^b   Kim, Soon Bae ^a  

^a Departments of Internal Medicine Nephrology   (United States)

^b University of Ulsan   (South Korea)

Author keywords

Closure time; Desmopressin; In vitro; Platelet dysfunction; Uremia

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; BLOOD CLOTTING FACTOR 8; COLLAGEN; DESMOPRESSIN; FIBRINOGEN; SODIUM CHLORIDE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSURE TIME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HUMAN; HYPONATREMIA; IN VITRO STUDY; MALE; MEASUREMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; TIME FACTORS; UREMIA;

EID: 74249097199     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276576     Document Type: Article

References (18)

1. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, Breithardt G: Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
2. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589. (Pubitemid 39426390)
3. Kaw D, Malhotra D: Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322. (Pubitemid 44091707)
4. Mannucci P, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman T: Deamino-8- D -arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12. (Pubitemid 13211265)
5. Rodgers RP, Levin J: A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20. (Pubitemid 20049639)
6. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA: Description of an in vitro platelet function analyzer - PFA- 100. Semin Thromb Hemost 1995; 21(suppl 2):106-112.
7. Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P: Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-39. (Pubitemid 29368770)
8. Francis J, Francis D, Larson L, Helms E, Garcia M: Can the platelet function analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999; 10: 132-136. (Pubitemid 29182281)
9. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL: Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 483-490. (Pubitemid 37138774)
10. Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P: Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003; 42: 746-751. (Pubitemid 37187375)
11. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M: Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007; 5: 2393-2398. (Pubitemid 350154348)
12. Cho YU, Jang S, Park CJ, Chi HS: Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci 2008; 38: 247-253.
13. Gralnick H, McKeown L, Williams S, Shafer B, Pierce L: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85: 806-810. (Pubitemid 19020525)
14. Kim SB, Chi HS, Park JS, Hong CD, Yang WS: Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 1999; 33: 312-317.
15. Zwaginga J, Ijsseldijk M, Beeser-Visser N, de Groot P, Vos J, Sixma J: High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 1990; 75: 1498-1508. (Pubitemid 20114890)
16. Chen KS, Huang CC, Leu ML, Deng P, Lo SK: Hemostatic and fibrinolytic response to desmopressin in uremic patients. Blood Purif 1997; 15: 84-91. (Pubitemid 27135353)
17. Franchini M: The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 2007; 82: 731-735. (Pubitemid 47221656)
18. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, Ordinas A: Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999; 84: 614-619. (Pubitemid 29334317)